- Home
- KROS vs BCYC Comparison
KROS vs BCYC Comparison
Compare KROS & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KROS
- BCYC
- Stock Information
- Founded
- KROS 2015
- BCYC 2009
- Country
- KROS United States
- BCYC United Kingdom
- Employees
- KROS N/A
- BCYC N/A
- Industry
- KROS Biotechnology: Pharmaceutical Preparations
- BCYC Biotechnology: Pharmaceutical Preparations
- Sector
- KROS Health Care
- BCYC Health Care
- Exchange
- KROS Nasdaq
- BCYC Nasdaq
- Market Cap
- KROS 565.0M
- BCYC 492.1M
- IPO Year
- KROS 2020
- BCYC 2019
- Fundamental
- Price
- KROS $15.71
- BCYC $7.96
- Analyst Decision
- KROS Buy
- BCYC Buy
- Analyst Count
- KROS 14
- BCYC 11
- Target Price
- KROS $20.56
- BCYC $22.91
- AVG Volume (30 Days)
- KROS 370.6K
- BCYC 303.4K
- Earning Date
- KROS 11-05-2025
- BCYC 10-30-2025
- Dividend Yield
- KROS N/A
- BCYC N/A
- EPS Growth
- KROS N/A
- BCYC N/A
- EPS
- KROS 0.47
- BCYC N/A
- Revenue
- KROS $232,844,000.00
- BCYC $19,281,000.00
- Revenue This Year
- KROS $5,998.31
- BCYC N/A
- Revenue Next Year
- KROS N/A
- BCYC N/A
- P/E Ratio
- KROS $33.68
- BCYC N/A
- Revenue Growth
- KROS 85820.30
- BCYC N/A
- 52 Week Low
- KROS $9.12
- BCYC $6.10
- 52 Week High
- KROS $72.37
- BCYC $28.67
- Technical
- Relative Strength Index (RSI)
- KROS 53.11
- BCYC 58.20
- Support Level
- KROS $15.00
- BCYC $7.40
- Resistance Level
- KROS $16.57
- BCYC $8.69
- Average True Range (ATR)
- KROS 0.53
- BCYC 0.38
- MACD
- KROS -0.06
- BCYC 0.11
- Stochastic Oscillator
- KROS 47.77
- BCYC 62.23
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.